PBSV Pharma-Bio Serv, Inc.

PBSV financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1304161 Exchange: OTC SIC: 8742 (Services-Management Consulting Services) Latest filing: 10-Q filed Sep 14, 2026 Data checked: Oct 21, 2026
Showing 3 of 16 annual and 0 of 64 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$13.64M (Apr 2025)
Industry (SIC)
8742 Services-Management Consulting Services
Fiscal Year End
October (1031)
Phone
787-278-2709
EIN
200653570
Headquarters
DORADO, PR, 00646
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: LAWRENCE CONSULTING GROUP INC (2004–2006)

▼ Key Metrics (TTM)

As of Jul 31, 2026
Financials
Revenue
$9.48M
Net Income
$251.53K
Total Assets
$11.44M
Total Equity
$10.44M
Total Debt
-
Free Cash Flow
$-421.36K
Ratios
Gross Margin
32.3%
Operating Margin
-1.6%
Net Margin
2.7%
Return on Equity
2.4%
Return on Assets
2.2%
Current Ratio
11.3x
FCF / Assets
-3.7%

▼ FY 2025 Summary Analysis

Annual report ending Oct 31, 2025

Overview and Growth

Fiscal 2025 results for Pharma-Bio Serv, Inc. combined $9.00M of revenue with net loss of $100.46K and an operating cash outflow of $214.89K. At $9.00M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. The top line contracted 5.3% from $9.51M in fiscal 2024; this top-line contraction left the company with a smaller revenue base. The company reported diluted EPS of -$0.00, adding a shareholder-level measure to the absolute income figures considered below. Total assets stood at $13.65M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. The revenue-to-assets relationship was 0.66x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $2.91M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross margin was 32.3%, so that share of each revenue unit remained after the cost of revenue reported for the period. The reported operating result was an operating loss of $637.66K, reflecting costs that exceeded gross profit. Relative to revenue, the operating deficit measured 7.1%, showing the shortfall after operating costs. The company ended the period with a net loss of $100.46K, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 1.1% after all recognized items. The company reported negative EBITDA of $577.80K, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The pretax result was a loss of $94.26K, establishing the deficit before tax effects. The pretax loss equaled 1.0% of revenue, measuring the pre-tax deficit against sales. Income tax expense totaled $6.20K, providing the reported tax component that separates pretax and after-tax earnings. Relative to period-end equity, the net loss represented 0.8%. The net loss equaled 0.7% of period-end assets, showing the deficit relative to the asset base. The net loss narrowed to $100.46K from $777.62K in fiscal 2024.

Liquidity and Capital Structure

Total assets were $13.65M, supported by $1.74M of liabilities and $11.91M of shareholder equity. At period end, current assets of $13.39M compared with current liabilities of $1.74M, defining the company’s short-term resource position. Current assets covered current liabilities by 7.7x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $3.38M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 194.3% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The equity-to-assets relationship was 87.3%, placing book capital against the total resource base. Relative to total assets, liabilities measured 12.7%, complementing the separate equity-based view of the company’s capital structure. The cash-to-assets relationship was 24.8%, comparing reported cash and equivalents with the full positive asset balance. Compared with $16.29M in fiscal 2024, the current asset base moved 16.2% and finished lower. Against $13.72M of equity in fiscal 2024, the current book-equity balance moved 13.1% and ended lower. Compared with $6.77M in fiscal 2024, the current cash balance moved 50.1% and finished lower.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $214.89K, showing that operations absorbed cash during the period. Capital expenditures used $6.64K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. Operating cash flow and capital spending combined to leave a $221.53K cash deficit after capital spending. The free-cash-flow deficit equaled 2.5% of revenue, showing the post-investment cash shortfall relative to sales. The cash deficit after capital spending represented 1.6% of the period-end asset base.
Based on the annual report for the fiscal year ending Oct 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Pharma-Bio Serv, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $9.00M $9.51M $16.98M
Cost of Revenue $6.09M $6.99M $11.91M
Gross Profit $2.91M $2.52M $5.07M
OPERATING EXPENSES
SG&A Expense $3.55M $3.80M $3.95M
Operating Income $-637.66K $-1.29M $1.12M
NON-OPERATING INCOME / EXPENSE
Interest Income $37.53K $245.82K $320.08K
Other Income/Expense $543.40K $532.14K $570.08K
Pretax Income $-94.26K $-755.45K $1.69M
Income Tax $6.20K $22.17K $377.31K
Net Income $-100.46K $-777.62K $1.31M
PER SHARE & SUPPLEMENTAL
Diluted EPS $0.00 $-0.03 $0.06
Diluted Shares 22.96M 22.97M 23.00M
EBITDA $-577.80K $-1.26M $1.17M
Depreciation & Amortization $59.87K $23.31K $48.09K
Balance Sheet
ASSETS
Cash & Equivalents $3.38M $6.77M $10.45M
Short-term Investments $7.48M $5.98M $4.53M
Accounts Receivable $2.36M $2.51M $3.94M
Current Assets $13.39M $15.70M $19.40M
PP&E (Net) $116.06K $169.28K $32.85K
Other Noncurrent Assets $120.75K $225.60K $111.67K
Noncurrent Assets $266.20K $593.48K $500.96K
Total Assets $13.65M $16.29M $19.90M
LIABILITIES
Accounts Payable $991.17K $1.13M $1.47M
Current Liabilities $1.74M $1.89M $2.15M
Noncurrent Liabilities $0 $689.74K $1.62M
Total Liabilities $1.74M $2.58M $3.78M
EQUITY
Common Stock $2.35K $2.35K $2.35K
Additional Paid-in Capital $1.68M $1.64M $1.60M
Retained Earnings $10.53M $12.35M $14.85M
Accumulated OCI $278.05K $262.38K $210.27K
Total Equity $11.91M $13.72M $16.13M
Total Liabilities & Equity $13.65M $16.29M $19.90M
SUPPLEMENTAL
Shares Outstanding 22.91M 22.96M 22.96M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-214.89K $-566.70K $1.89M
Capital Expenditures $6.64K $159.74K $7.25K
Cash from Investing $-1.47M $-1.36M $-4.22M
Cash from Financing $-1.75M $-1.73M $-1.76M
Free Cash Flow $-221.53K $-726.44K $1.88M
Beginning Cash (CFS) $6.77M $10.45M $14.46M
Net Change in Cash $-3.43M $-3.66M $-4.09M
Effect of FX on Cash $44.49K $-17.63K $68.87K
Calculated Ending Cash $3.38M $6.77M $10.45M
Cash per BS $3.38M $6.77M $10.45M
Cash scope difference (CFS − BS) - - -
Cash per CFS $3.38M $6.77M $10.45M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Pharma-Bio Serv, Inc.'s annual revenue?

Pharma-Bio Serv, Inc. reported $9.48M in revenue for trailing twelve months (ending July 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Pharma-Bio Serv, Inc. profitable?

Yes. Pharma-Bio Serv, Inc. reported $251.53K in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does Pharma-Bio Serv, Inc. generate free cash flow?

No. Free cash flow was $-421.36K for trailing twelve months. Operating cash flow was $-414.89K.